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Background: The high burden and rising incidence of cardiovascular disease (CVD) in resource constrained
countries necessitates implementation of robust and pragmatic primary and secondary prevention strategies. Many
current CVD management guidelines recommend absolute cardiovascular (CV) risk assessment as a clinically sound
guide to preventive and treatment strategies. Development of non-laboratory based cardiovascular risk assessment
algorithms enable absolute risk assessment in resource constrained countries.
The objective of this review is to evaluate the performance of existing non-laboratory based CV risk assessment
algorithms using the benchmarks for clinically useful CV risk assessment algorithms outlined by Cooney and colleagues.
Methods: A literature search to identify non-laboratory based risk prediction algorithms was performed in MEDLINE,
CINAHL, Ovid Premier Nursing Journals Plus, and PubMed databases. The identified algorithms were evaluated using
the benchmarks for clinically useful cardiovascular risk assessment algorithms outlined by Cooney and colleagues.
Results: Five non-laboratory based CV risk assessment algorithms were identified. The Gaziano and Framingham
algorithms met the criteria for appropriateness of statistical methods used to derive the algorithms and endpoints. The
Swedish Consultation, Framingham and Gaziano algorithms demonstrated good discrimination in derivation datasets.
Only the Gaziano algorithm was externally validated where it had optimal discrimination. The Gaziano and WHO
algorithms had chart formats which made them simple and user friendly for clinical application.
Conclusion: Both the Gaziano and Framingham non-laboratory based algorithms met most of the criteria outlined by
Cooney and colleagues. External validation of the algorithms in diverse samples is needed to ascertain their
performance and applicability to different populations and to enhance clinicians’ confidence in them.
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Cardiovascular disease (CVD) continues to be the leading
cause of morbidity and mortality in the developed world
despite abundance of resources and well developed health
care systems [1]. In recent years, a new trend has been ob-
served in developing countries where cardiovascular dis-
ease has become the overall leading cause of death due in
part to the ongoing epidemiological transition from infec-
tious to non-communicable diseases. Currently 80% of the
global burden of CVD is in developing countries [2-4].* Correspondence: Jacob.Kariuki@umb.edu
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tracted double burden of disease in developing countries
which are also plagued by underdeveloped and fragile
health care systems [2]. In the backdrop of the looming
public health crisis, most governments in developing
countries such as Sub-Saharan Africa still allocate 80% of
their total health budgets to acute communicable diseases
[5]. The same trend of skewed allocation of resources has
been followed by major donor agencies including the
World Health Organization (WHO). A comparative ana-
lysis of WHO 2008–2009 budget by Stuckler and colle-
gues [5] revealed that only 12% of WHO total budget was
earmarked for non-communicable diseases, while 87%
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source constrained countries necessitates that robust and
pragmatic primary and secondary prevention strategies be
implemented with urgency. Many current CVD manage-
ment guidelines recommend absolute cardiovascular (CV)
risk assessment as a clinically sound guide to preventive
and treatment strategies [3,6]. Calculating the patient’s ab-
solute risk for CVD enables clinicians to estimate the likeli-
hood that a particular constellation of risk factors will
contribute to the development of a CVD related morbidity
or mortality over a specific period of time [7,8].
Absolute risk estimates can be useful in raising CVD
awareness, and in motivating adherence to recommended
lifestyle changes or treatment. In clinical practices across
many developed countries, CV risk assessment algorithms
have been mainly used to identify individuals at high risk
for developing CVD within a specified period of time, usu-
ally 10 years, and to select those individuals for more in-
tensive preventive and treatment interventions [8].
A proactive preventive strategy that incorporates the ab-
solute risk approach could potentially have a major impact
in lowering the incidence and the burden of CVD in re-
source constrained countries. By directing the scarce re-
sources toward those in greatest need, the disease burden
associated with CVD could be reduced without the ex-
pense of unnecessary treatment and associated adverse ef-
fects to those at low risk [3]. However, while the absolute
risk approach could be beneficial in resource constrained
countries, the widely used CV risk assessment algorithms
are based on laboratory measures that are not readily
available in resource constrained countries [9,10].
In recent years, there have been significant efforts to de-
velop non-laboratory based cardiovascular risk assessment
algorithms that are feasible for resource constrained coun-
tries. However, unlike their laboratory based counterparts,
the non-laboratory based algorithms have not been critic-
ally evaluated using rigorous criteria. The purpose of this
systematic review of the literature is to evaluate the per-
formance of existing non-laboratory based CV risk assess-
ment algorithms using the benchmarks for clinically
useful CV risk assessment algorithms outlined by Cooney
and colleagues [6].
Methods
A literature search was performed in MEDLINE, CINAHL,
Ovid Premier Nursing Journals Plus, and PubMed data-
bases. The key words used in the search were: Non-
laboratory based CVD risk assessment algorithms OR
Non-laboratory based CVD risk function OR Non-
laboratory based CVD risk assessment system OR simple
office-based CVD risk prediction function. Additionally, a
search for related articles was done within the databases
and using the bibliographies of the selected articles. The
inclusion criteria required the full text report to be writtenin English, focused on algorithms for primary prevention of
CVD, and have human subjects aged nineteen years old
and above. All the included articles were based on studies
which had ethical clearance from the relevant institutional
review boards. We excluded secondary sources and studies
focusing on algorithms for secondary prevention of CVD
and special populations. No other limits were employed.
The search strategy was guided by the PRISMA model [11].
The methodological soundness of each of the indenti-
fied CVD risk assessment algorithms was evaluated
using the benchmarks for clinically useful cardiovascular
risk assessment algorithms outlined by Cooney and col-
leagues [6] shown in Table 1.
The appropriateness of the statistical methods used to de-
rive the function was measured by analyzing the represen-
tativeness of the algorithm’s derivation sample, statistical
power, statistical methods used, and end point predicted by
the function. Performance was evaluated by analyzing dis-
crimination (using Area under Receiver Operating Charac-
teristics), calibration (using Hosmer-Lemeshow goodness of
fit testing), and sensitivity of the algorithms in their deriv-
ation and external datasets. Usability was assessed by
weighing the impact of algorithm’s format on its use in clin-
ical settings. Inclusion of appropriate risk factors was evalu-
ated by assessing the incorporation in the algorithm of
major risk factors which are known to be prevalent in the
target population. Measurable health gains that have been
associated with the use of the algorithms were measured by
assessing any tangible clinical benefits associated with use
of the algorithms.
Results
When the search criteria were applied, MEDLINE yielded 3
articles, CINAHL 1 article, and PubMed 6 articles. All the
articles retrieved in MEDLINE and CINAHL were relevant,
while two of those retrieved from PubMed were excluded
because they were editorial reviews. When the same
search criteria were applied in Ovid Premier Nursing
Journals Plus, 270 articles were retrieved. Of the total
280 articles, 274 (97.9%) could not be included in the
primary review because they failed to meet the inclu-
sion/exclusion criteria after reviewing their titles and
abstracts. The PRISMA diagram in Figure 1 describes
the flow of the search. The six relevant articles identified
focused on five non-laboratory based CV risk assessment
algorithms namely: Framingham non-laboratory based al-
gorithm [12], Gaziano non-laboratory based algorithm
[9,13], WHO/ISH non-laboratory based algorithms [14],
Swedish Consultation-based method [15], and the UK
General Practice model [16].
The five identified non-laboratory based cardiovascular
risk assessment algorithms were developed for use in pri-
mary prevention of CVD in resource constrained settings
[9,12,14-16]. Table 2 outlines the covariates, end points
Table 1 Cooney’s criteria for evaluating clinically useful risk assessment algorithms
1 Appropriateness of statistical methods used to derive the function.
• Representativeness of the algorithm’s derivation sample, optimal statistical power and methods, and clarity of end point predicted by the function.
2 Performance of the function: internal and external validity.
• Discrimination, calibration, and sensitivity of the algorithm(s) in the derivation and external datasets.
3 Usability of the algorithm.
• Impact of an algorithm’s format on its use and uptake in clinical settings.
4 Inclusion of appropriate risk factors.
• Inclusion of major risk factors known to be prevalent in the target population.
5 Measurable health gains associated with the use of the algorithm(s).
• Tangible clinical benefits associated with use of the algorithm(s).
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risk assessment algorithms. The identified five algorithms
were critically appraised using Cooney’s criteria for evalu-
ating clinically useful risk assessment algorithms [6] out-
lined in Table 1 and described under the methods section.
Evaluating the algorithms using Cooney’s criteria
Appropriateness of methods used to derive the function
According to Cooney and colleagues [6] a clinically useful
CV risk assessment algorithm should be derived from an
adequately powered sample which is representative of the
population to which the algorithm is to be applied. In
addition, valid statistical methods should be employed,
and the end point(s) predicted by the algorithm should be
clearly defined to enable standardization across popula-
tions. Table 3 outlines the sample characteristics, statisticalFigure 1 PRISMA flow diagram. Outlines the literature search flow.methods and validation of the non-laboratory based CV
risk assessment algorithms.
Sample characteristics of the algorithms The Gaziano
non-laboratory based algorithm was derived from a sam-
ple of 6186 participants of the first National Health and
Nutrition Examination Survey Epidemiologic Follow-up
Study (NHEFS) who were free from CVD and cancer
[9]. NHEFS was a prospective cohort study of NHANES
I participants aged between 25 to 74 years at their initial
assessment between 1971 and 1975 [17]. The specific
sample used to derive the Gaziano non-laboratory based
algorithm included 3349 women and 2837 men who
were ethnically and racially diverse [9]. Therefore, this
algorithm may be applied across ethnic and racial groups
aged 25 to 74 years.
Table 2 Covariates, end points and risk categories of non-laboratory based CV risk prediction algorithms
Algorithms Covariates Endpoints Risk
categories








M or F 30-74 • Yes, current
smoker
Systolic 120-160 • Yes to
current
treatment
kg/m2 • Yes, on insulin or oral
hypoglycemic medications,
or FBS ≥126 mg/dl
NA 10-year risk of general and
individual CVD events (coronary,
cerebro-vascular, and peripheral











M or F 35-74 • Yes, current/
former smoker
Systolic 111- 180 • Yes to current
treatment
kg/m2 • Yes, diabetes
self reported















M or F 40-70 • Yes, current/
former smoker
<1 yr
Systolic 140-180 NA NA • Yes, on insulin or oral
hypoglycemic drugs; or




10-year combined risk for acute
myocardial infarction and











M or F 40-59 • Yes, current. Systolic ≥140 or
Diastolic ≥90









Time to first fatal or nonfatal
CVD, which include;
cardiovascular death, angina, MI,








F 60-79 • Current Systolic 123-173 NA NA NA Self-rated
health
CHD and CVD events























Table 3 Sample characteristics, statistical methods and validation of non-laboratory based CV risk prediction algorithms
Algorithms Methods Internal validation External validation
Framingham non-lab
based algorithm [12]




No external validation reported
Discrimination (C-statistics): 0.749 0.785
Calibration (χ2) 13.61 10.24
Sample: 8491 participants (4522 women)
aged 30 to 74 years who were free of CVD.
Sensitivity/specificity
(20%, 10 yrs risk threshold)
(48/85)% (58/83)%
Baseline data: 1968 to 1971,
1971 to 1975, 1984 to 1987
Comparative analysis [12] (General CVD risk)
Non-lab Framingham
vs. Lab-Framingham-D’Agostino
C-statistics (men) 0.749 0.763
C-statistics (women) 0.785 0.793
Calibration χ2 (men) 13.61 13.48
Analysis: Cox proportional-
hazards regression
Calibration χ2 (women) 10.24 7.79
Gaziano non-lab based
algorithm [9]
Design: Prospective cohort study
of NHANES I Epidemiologic
Follow-up Study (NHEFS)
Men Women C-statistics: 0.782 Men 0.807 Women
Calibration (χ2): Not assessedC-statistics: 0.783 0.831
Calibration: (χ2) 6.61 3.45
Sample: 6186 subjects (3349 Women)
aged between 25 to 74 yrs
without CVD or cancer.
Sensitivity/specificity: Comparative analysis: Gaziano algorithm
was compared with 4 lab based algorithms
as follows: Framingham-D’Agostino-2008;
Framingham-Anderson; [20] SCORE low;
SCORE high [21].
30%, 5 yrs risk threshold: (8.8/98.6)% (5.1/99.5)%
20%, 5 yrs risk threshold: (24.8/93.7)% (17.6/97.7)%
Baseline data: 1971 and 1975,
1982–84,1987, and 1992
Comparative analysis [9] (CVD risk) C-statistics (men) respectively:
Gaziano vs. Lab-Framingham-Anderson [20] 0.782; 0.772; 0.778; 0.785; and 0.784.
Analysis: Cox proportional-
hazards regression
C-statistic (men) 0·821 0.820 C-statistics (women) respectively:
0.807; 0.832; 0.821; 0.792; and 0.793.
C-statistic (women) 0·860 0.858
χ (men) 6.61 6.70
χ2 (women) 3.45 6.62
WHO/ISH cardiovascular
risk prediction charts [14]
Design: Relative risks associated with CV risk factors
were obtained from the comparative risk assessment
project; these were combined with estimated absolute
risks for each WHO sub region based on global burden
of disease study.
C-statistics: Not reported.
No external validation reported
Sample: from theoretical dataset. Calibration (χ2): Not reported.



















Table 3 Sample characteristics, statistical methods and validation of non-laboratory based CV risk prediction algorithms (Continued)
Swedish consultation
based method [15].
Design: A cross-sectional, population-based screening
study with 17-year follow-up in Southern Sweden.
C-statistics (Overall): 0.794
Calibration (χ2): Not reported.
Sample: 689 individuals (349 men) without CVD. Sensitivity/specificity. Not reported
Baseline data: 1989 to May 1990 Comparative analysis [15]
No external validation reported
Consultation vs. SCORE [21]
Analysis: Cox proportional-hazards regression C-statistic: 0.794 0.767
Calibration (χ2) Not reported.
Consultation vs. extensive lab method [15].
C-statistic: 0.794 0.806
Calibration (χ2): Not reported.
UK General Practice
(GP) model [16].
Design: Prospective cohort study of British
Women Heart and Health study.
CHD CVD
No external validation reported
C-statistics: 0.66 0.67
Calibration (χ2) Not reported
Sample: 3582 women aged 60 to
79 years without CVD.
Sensitivity/specificity:
30%, 10 yrs risk threshold: (10/95)% (38/79)%




GP model vs. Framingham [20]
C-statistic: 0.67 0.66
Calibration (χ2) Not reported.
GP model vs. expanded
Framingham [16].
C-statistic: 0.66 0.64
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no specified sample. Rather they were formulated using a
hypothetical dataset created for each of the six WHO re-
gions based on the risk factor prevalence mapped by an
earlier Collaborative Risk Assessment Project [3]. It is
therefore difficult to ascertain whether the hypothetical
dataset reflected characteristics typical of the populations
targeted by the WHO/ISH non-laboratory based algo-
rithms, and whether the algorithm would perform as
projected.
The Swedish Consultation based method was derived
from a sample of 689 individuals, from Southern Sweden,
without CVD at baseline. The population-based approach
of the study ensured that all inhabitants aged 40 to 59 years
in So¨dera°kra, Southern Sweden were invited to partici-
pate in the cardiovascular risk-factor screening project.
The sample was balanced according to gender, with 340
women and 349 men participating [15]. However, since
the algorithm was derived in a relatively middle aged white
population, its applicability to older and racially diverse
populations is unknown. In addition, the sample may not
be adequately powered since it is relatively small com-
pared to the samples used to derive other algorithms.
The UK General practice model was derived from a pro-
spective cohort sample of 3582 participants of the British
Women Heart and Health study [16]. All the participants
in this study were women aged 60 to 79 years without
CVD at baseline. As such, the UK General practice model
may not be well suited to predict CV risk in younger
women and male populations, but it is likely to be more
precise with the older female populations compared to the
other four algorithms.
The Framingham non-laboratory based algorithm
was derived from a population based sample of 8491
Framingham study participants and their offspring
who were free from CVD [12]. A total of 4522 women
and 3969 men aged 30 to 74 years were included in
the study. At the inception of the study, the town of
Framingham was an industrial trading center inhabited
by white middle class families [18]. Consequently, the
Framingham study participants are considered repre-
sentative of the white middle class population in the
North Eastern United States.
Since the Framingham, UK General Practice model
and Swedish Consultation based method were derived
from predominantly white samples, questions remain un-
answered about their applicability in racially/ethnically di-
verse population. Taken at face value, these algorithms
may be construed to be inappropriate for non-white
populations. In their systematic review of risk scoring
methods, Beswick and colleagues [10] reported that
Framingham-based algorithms had poor calibration in
certain ethnic groups, and underestimated risk in
socio-economically deprived populations. Whereas theapplicability of Framingham based algorithms to different
populations continues to be debated, proponents of broad
applicability algorithms to diverse populations cite the
INTERHEART study’s revelation that the nine major
modifiable risk factors for CVD account for up to 90% risk
of MI incident across a wide range of cultural, ethnical
and geographical regions around the globe [1,4].
The idea of broad applicability of algorithms to diverse
populations has been supported by Beswick and colleagues
[10]. Although they reported poor performance of Framing-
ham based algorithms in certain ethnicities, such as the
Hispanics, they also observed that the algorithms per-
formed reasonably well in predicting coronary heart disease
death and myocardial infarction for white and black popu-
lations within 5 years of follow-up. In addition, recalibration
of Framingham functions enhanced predicted levels of ab-
solute risk in these populations. Therefore, there is convin-
cing evidence that CV risk prediction algorithms can be
applicable in populations with different racial and ethnic
profiles from their derivation samples.
Statistical methods and endpoints The Swedish Con-
sultation based method, the non-laboratory based
Framingham and Gaziano algorithms were derived using
Cox proportional-hazards regression [9,12,15] while the
UK General Practice model was derived using Weibull
proportional hazards survival model [16]. The WHO/ISH
non-laboratory based algorithms have not specified the
statistical methods used to derive their functions. Over-
all, Cox and Weibull proportional-hazards regression
approaches are considered superior to logistic regres-
sion because they account for variable follow-up times
and losses to follow-up. However, unlike the Weibull
method which imposes a parametric function on the
baseline survival, the Cox method has an additional ad-
vantage of not making assumptions regarding the shape
of the underlying survival [6,19]. Therefore, the latter
approach may be more suitable for this application.
The endpoints of the Framingham non-laboratory based
algorithm are clearly described as general and individual
fatal and non-fatal CVD events that include; coronary, cere-
brovascular and peripheral arterial disease, and heart failure
[12]. On the other hand, the Gaziano non-laboratory based
algorithm endpoints are first time fatal and non-fatal CVD
events that include myocardial infarction, stroke, congest-
ive heart failure, and coronary revascularization [9]. The
WHO/ISH non-laboratory based algorithms endpoints are
specified as fatal and non-fatal acute myocardial infarction
and stroke [3], while the Swedish Consultation based
method endpoints are first fatal or nonfatal CVD, which
include; cardiovascular death, angina, myocardial infarc-
tion, coronary artery bypass graft surgery, percutaneous
transluminal angioplasty, stroke and peripheral arterial
disease [15]. The UK General Practice model endpoints
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myocardial infarction, coronary artery bypass graft surgery
or angioplasty and stroke [16].
The endpoints for the Framingham non-laboratory based
algorithm were ascertained through hospitalization records,
physical examinations, medical records, and communica-
tion with personal physicians; [12] while the endpoints for
the Gaziano non-laboratory based algorithm were estab-
lished through review of mortality records, hospitalization
records, medical history, medical records, pathology re-
ports, and electrocardiographs [9]. The Swedish Consult-
ation model endpoints were ascertained through review of
cardiovascular mortality and in-hospital care for CVD; [15]
while the UK General Practice model endpoints were con-
firmed through a follow-up medical record review [16].
Table 2 outlines endpoints of the five non-laboratory based
CV risk assessment algorithms.
Whereas all the five non-laboratory based algorithms
have clearly defined their endpoints, significant distinc-
tions exist. The Gaziano non-laboratory based algorithm,
GP model and the WHO/ISH non-laboratory based algo-
rithms use a combination of CHD/CVD events as their
endpoints, while the Framingham non-laboratory based
algorithm and the Consultation model focus on general
CVD risk rather than hard coronary events. Cooney and
colleagues criteria [6] considers general CVD risk as the
most appropriate primary endpoint since atherosclerosis
may be manifest outside the coronary vessels, for instance
as stroke or peripheral vascular disease. Another signifi-
cant characteristic of the Framingham non-laboratory
based algorithm is that it retains the ability to estimate the
risk of cause-specific outcomes such as cerebrovascular
events. This is important because cause-specific outcomes
such as stroke are important in low-risk countries and
older populations [19].
Performance of the algorithms
Performance of a cardiovascular risk assessment algorithm
is assessed through internal and external validation. The
main approaches for measuring the performance include
discrimination, calibration, and reclassification [6].
Discrimination is the ability of an algorithm to assign a
higher risk to those who will develop the end point com-
pared to those who will not, and it is frequently measured
using Area Under Receiver Operating Characteristic Curve
(AUROC) or Harrell’s C statistic. An AUROC of 1 denotes
perfect discrimination whereas 0.5 equates to chance. Al-
though the C statistic of CV risk assessment algorithms
rarely exceeds 0.8, a commendable algorithm should have a
C statistic of 0.75 or higher [6,16]. In addition threshold
discrimination, operationalized by sensitivity and specificity,
is used to define low/high risk populations and treatment
decisions are made in reference to this threshold. There-
fore, the sensitivity (positive predictive value) and specificity(negative predictive value) of CV risk assessment algo-
rithms at different cut points for low and high risk should
always be reported [6].
Calibration is a measure of the agreement between the
predicted outcomes and actual outcomes. It is frequently
assessed using either Hosmer-Lemeshow goodness of fit
testing (χ2) or predicted to observed ratios. Goodness of
fit (χ2) values below 20 are considered good fit, whereas
predicted to observed ratios closer to 1 are considered bet-
ter fit [6]. Generally, discrimination and calibration are
assessed as part of internal and external validation of CV
risk assessment algorithms. Table 3 outlines the results of
the internal and external validation of the five non-
laboratory based CV risk assessment algorithms.Internal validation Internal validation is the assessment
of an algorithm’s performance in the dataset from which
it was derived. Although it is important in evaluating the
mathematical performance and the appropriate fit of a
new algorithm, it is not useful in comparing different al-
gorithms as it is inherently biased in favor of the new al-
gorithm [6].
The internal validation of the Framingham non-
laboratory based algorithm demonstrated good discrim-
ination (c statistic 0.749 for men and 0.785 for women)
and calibration (χ2 13.61 in men and 10.24 in women).
Sensitivity at the highest risk threshold (>20%, 10-year
risk) was approximately 48% for men and 58% for
women while specificity was 85% for men and 83% for
women [12].
The Gaziano non-laboratory based algorithm internal val-
idation demonstrated good summary discrimination (C sta-
tistics 0 · 783 men and 0 · 831 women) and calibration (χ2
6.61 for men and 3.45 for women). However, its sensitivity
was 5.1% for women and 8.8% for men and specificity
99.5% for women and 98.6% for men at the highest risk
threshold (30%, 5-year risk) [9].
The internal validation of the UK General Practice
model revealed a summary C statistics of 0.67 for CVD
and 0.66 for CHD. At the highest risk threshold (30%,
10-year risk) sensitivity for CVD was 38% and specificity
79% whereas for CHD sensitivity was 10% and specificity
95%. At a lower risk threshold (15%, 10-year risk) sensi-
tivity for CVD was 85% and specificity 30%, whereas
sensitivity was 44% and specificity 74% for CHD [16].
Calibration was not reported.
Internal validation of the Swedish Consultation based
method revealed a good summary discrimination (C statis-
tics 0.794) which is not gender specified [15]. However,
the threshold discrimination (sensitivity and specificity)
and calibration of the Consultation based method are not
reported. The internal validation of the WHO/ISH non-
laboratory based algorithms was not reported.
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the Gaziano non-laboratory based algorithm had the high-
est overall discrimination for men and women compared to
the other algorithms. In regard to the clinically important
threshold discrimination, it appears that the Framingham
non-laboratory based algorithm was superior in sensitivity
compared to Gaziano and the UK General Practice model.
However, it is important to point out that the Gaziano non-
laboratory based algorithm has the highest risk threshold
compared to Framingham non-laboratory based algorithm
and the UK General Practice model, and covers a shorter
period of time (30%, 5-year risk). Nevertheless, even at a
lower risk threshold (20%, 5-year risk) the Gaziano non-
laboratory based algorithm still had low sensitivity (17.6%
women, 24.8% men). At a lower risk threshold (15%, 10-
year risk) the UK General Practice model sensitivity for
CVD improved dramatically (from 38% to 85%) albeit at
the expense of specificity.
A laboratory based algorithm [12] was derived in the
same dataset as the Framingham non-laboratory based al-
gorithm. This makes it possible to do an appropriate com-
parison for the internal validation. The laboratory based
Framingham D’Agostino-2008 covariates include age, total
cholesterol, HDL cholesterol, systolic blood pressure, anti-
hypertensive medication use, current smoking, and diabetes
status. The Framingham non-laboratory based algorithm
has the same covariates but substitutes BMI for cholesterol.
When the Framingham non-laboratory based algorithm
was compared to the laboratory based Framingham
D’Agostino-2008, it had similar discrimination (C statistics
0.749 versus 0.763 for men and 0.785 versus 0.793 for
women) and equally good calibration (χ2 13.61 versus
13.48 in men and χ2 10.24 versus 7.79 in women). Both
algorithms were also similar in sensitivity (48% of men and
58% of women versus 49% of men and 60% of women)
and specificity (85% for men and 83% for women versus
85% and 84%) respectively.
The internal validation of the Gaziano non-laboratory
based algorithm also involved a comparison with a labora-
tory based algorithm. The Gaziano non-laboratory based
algorithm was compared with the laboratory based
Framingham Anderson [20] whose covariates are; age,
systolic blood pressure, smoking status, total choles-
terol, reported diabetes status, and current treatment
for hypertension. The same risk factors are used by the
Gaziano non-laboratory based algorithm but again, BMI
is substituted for total cholesterol [9]. Although similar
discrimination and calibration were reported between
the two models (Table 3), inferences should be made
with caution because the comparison was done in the
dataset used to derive the Gaziano non-laboratory based
algorithm but not the Framingham-Anderson algorithm.
Therefore the process was inherently biased in favor of the
Gaziano non-laboratory algorithm.Likewise, the internal validation of the Swedish Con-
sultation based method involved a comparison with the
laboratory based SCORE algorithm [21], and an exten-
sive laboratory based method [15]. The Swedish Consult-
ation based method covariates include age, sex, present
smoking, diabetes, treated hypertension, measured blood
pressure, waist/height ratio and family history of CVD
(angina, myocardial infarction and stroke). The SCORE
covariates were; sex, age, present smoking, systolic blood
pressure and total cholesterol, while the extensive labora-
tory based method included; age, sex, present smoking,
blood pressure at baseline, waist/height ratio, family
history of CVD, serum triglycerides, serum LDL/HDL-
cholesterol, blood glucose, IGF-I, CRP and SDMA.
The Swedish Consultation based method was superior
to SCORE in discrimination (C-statistic 0.794 vs 0.767 re-
spectively), but the Extensive laboratory based method
had the highest discrimination (C-statistic 0.806). Again,
the higher discrimination observed with the Swedish Con-
sultation based method this comparative analysis should
be interpreted with caution, for it could be a result of the
comparison being done in the same dataset used to derive
the Swedish Consultation based method. At the same
time, the clinical value of the small improvement in dis-
crimination seen in the Extensive laboratory based method
should be weighed against the costs and inconveniences of
adding the extensive laboratory measures.
The internal validation of the UK General Practice model
also involved a comparison with the laboratory based
Framingham-Anderson [20] described earlier and an
expanded Framingham that included C-reactive protein
and fibrinogen. The covariates of UK General Practice
model included age, systolic blood pressure, smoking
habit, and self-rated health [16]. The UK General Practice
model had similar discrimination with Framingham-
Anderson (C statistics 0.67 versus 0.66) and the Expanded
Framingham (0.64). However, the three models fell
below the commendable C-statistic of 0.75 [16]. The low
discrimination is a major limitation of the UK General
Practice model, especially in the backdrop of the au-
thors’ acknowledgement that the discrimination or the
calibration of the model may worsen if it were used for
prediction in independent data. A summary of sample
characteristics, statistical methods and validation of
the five non-laboratory based CV risk prediction algo-
rithms is presented in Table 3.
External validation External validation is the assessment
of the performance of an algorithm in an external dataset.
It is considered a more appropriate approach in assessing
performance and applicability of an algorithm to different
populations because baseline survival and risk factors defi-
nitions used in the test are not a perfect match for those
in the algorithm’s derivation dataset [6].
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nally validated in a sample of 5,999 individuals drawn from
NHANES III dataset [13]. Pandya and colleagues [13] jus-
tify use of NHANES III dataset for external validation by
observing that sampling for each wave of NHANES was
conducted separately, and none of the individuals from the
NHANES I sample were intentionally included in the
NHANES III sample. Although NHANES III was a crossec-
tional study done between 1988 to 1994, CVD and CHD
events were ascertained using cause-specific mortality
which was available for adults up to 2006 [13].
The performance of the Gaziano non-laboratory based
algorithm was compared with two Framingham labora-
tory based algorithms (Framingham-D’Agostino-2008
[12]; Framingham-Anderson [20]) and the Systematic
COronary Risk Evaluation (SCORE) algorithms [21] for
high and low risk settings using cause-specific mortality
data. For the SCORE algorithms age was used as a measure
of exposure time to risk rather than a risk factor [21].
The covariates of the algorithms have been described
in the previous section.
Risk discrimination for each algorithm was assessed using
the algorithm-specific ranks, with 10-year CVD death as
the outcome of interest. The Gaziano non-laboratory based
algorithm had a C-statistics of 0.782 in men, and 0.807 in
women. In men, there was no significant difference in
risk discrimination between the Gaziano algorithm and
the other four laboratory-based algorithms. However in
women, the Gaziano non-laboratory based algorithm
had statistically significant lower C-statistics compared to
SCORE and Framingham-D’Agostino-2008 [13]. Table 3
tabulates the C-statistics of the four laboratory based algo-
rithms compared with the Gaziano non- laboratory based
algorithm.
The agreement between the algorithms based on the
risk threshold by the Adult Treatment Panel (APT) III
guidelines (10-year Framingham CHD risk >10%) was
high. Overall, 42.2% of men and 18.8% of women in the
study sample would be characterized as “high” risk. In this
sample, 91.9% of men and 94.6% of women were consist-
ently ranked as “high” or “low” risk by either the Gaziano
or laboratory based Framingham-D’Agostino-2008 algo-
rithms. Similar high agreements were noted with the other
three laboratory based algorithms as described in Table 3.
However, the external validation of the Gaziano non-
laboratory based algorithm did not assess calibration due
to lack of data on non-fatal events [13].
No articles were found focusing on external validation of
the Framingham non-laboratory based algorithm, WHO/
ISH non-laboratory based algorithms, Swedish Consult-
ation model or the UK General Practice model. However,
two studies were found questioning the accuracy of risk
classification by the WHO/ISH non-laboratory based algo-
rithms, the major concern being an observation that thealgorithms are not detailed enough for medium and high-
risk patients [22,23].
Usability of the algorithms
The value of a risk assessment algorithm depends on the
extent to which it is applicable for clinical practice. In clin-
ical decision-making, clinicians are more likely to use risk
assessment algorithms that are quick and easy to use [6,9].
The need for simple, user friendly risk algorithms is even
more acute in resource constrained settings where non-
physician health workers are increasingly being entrusted
with traditionally physician responsibilities such as screen-
ing for and managing chronic diseases.
The Gaziano non-laboratory based algorithm is available
in a gender specific chart format. All covariates of the al-
gorithm except treatment status for blood pressure are in-
cluded in the chart [9]. It is also worth noting that there is
an apparent overlap, in the published charts, of the BMI
categories. For instance a BMI of 25 may be placed in ei-
ther category 20–25 or 25–30. This overlap can be confus-
ing in clinical assessment even though the authors might
have a plausible explanation of how to deal with the ap-
parent overlaps.
The WHO/ISH non-laboratory based algorithms are
also available in gender specific charts which are custom-
ized for use according to the six WHO regions [3]. The
charts include all the covariates of the algorithm. Unlike
the Gaziano and WHO/ISH non-laboratory based algo-
rithms which are available in charts, the Framingham
non-laboratory based algorithm is available in an excel
spreadsheet format and an interactive online calculator
[12]. All risk factors are included in the spreadsheet and
electronic formats of the algorithm. The formats of the
Swedish Consultation based model and the UK General
Practice model are not specified.
Generally, charts are preferable to tables because they
are easy to use and inexpensive to produce [6]. Addition-
ally, the charts provide an optimal visual aid when explain-
ing the implications of elevated risk and treatment options
to the patient [10]. A randomized trial conducted in 37
medical practices in Scotland revealed that physicians and
nurses preferred charts to numerical tables because they
were easy to use within the time constrains of typical
clinic visits [24]. Therefore, concerning the ease of clinical
usability, the Gaziano and WHO/ISH charts are likely to
be preferred to the spreadsheet and electronic version of
Framingham non-laboratory based algorithm. Even when
an electronic version of an algorithm is easy to use, its ap-
plicability in low resource settings could be difficult due to
technological challenges.
For charts to attain their optimal utility Beswick and col-
leagues [10] contend that they ought to include all the risk
factors present in the full prediction model. The Gaziano
algorithm could be limited in this aspect because its charts
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included in the full prediction model, although this could
have been factored in the derivation of the charts.
Inclusion of appropriate risk factors
Although net reclassification index is considered a more
accurate measure for assessing the value of additional risk
factors compared to C-statistic [6,25], none of the five non-
laboratories based algorithm used it. All except the WHO/
ISH non-laboratory based algorithms reported their C-
statistic. Overall, C-statistic has been the most popular
metric for assessing the value of additional risk factors [25].
In the Swedish Consultation model, the appropriate-
ness of additional risk factors for CVD was evaluated by
Petersson and colleagues [15]. When serum triglycerides,
serum LDL-cholesterol/serum HDL-cholesterol, blood
glucose, IGF-I, CRP and SDMA were added to the Con-
sultation based model, only a slight improvement of the
C-statistic was observed (C-statistic 0.794 vs. 0.806). May
and colleagues [16] reported that the UK General Practice
model was superior to an expanded Framingham function
that included C-reactive protein and fibrinogen (C-statistic
0.67 vs. 0.64). As Petersson and colleagues [15] correctly
observe, it is not cost-effective or clinically prudent to
do such elaborate laboratory tests which are not associ-
ated with any significant improvement in risk discrimin-
ation [15].
Recognizing that all the potential risk factors for CVD
cannot be included in any risk assessment algorithm,
many authors have supported simplification of the risk al-
gorithms to enhance clinical utility. However, Beswick and
colleagues [10] caution against the other extreme end of
the continuum, oversimplification. They contend that fail-
ure to include adequate known risk factors in an algorithm
inevitably leads to unfavorable sensitivity and specificity.
This is a possible predicament of the WHO/ISH non-
laboratory based algorithms. Unlike the Gaziano and the
Framingham non-laboratory based algorithms, which sub-
stitute BMI for cholesterol, the WHO/ISH non-laboratory
based algorithms omits cholesterol measures without any
substitution. Although the real implications of the simpli-
fication are unknown because no information on discrim-
ination or reclassification has been provided for the
WHO/ISH non-laboratory based algorithms, there is real
potential for sensitivity and specificity to be unfavorably
affected.
Measurable health gains
Although there is general consensus that global risk as-
sessment is an important adjunct to CVD prevention and
management, there remains considerable debate about the
tangible clinical benefits associated with the use of cardio-
vascular risk algorithms [10]. Critics observe that small
randomized trials have been heterogeneous on measurablehealth gains associated with use of cardiovascular risk as-
sessment algorithms. However, most of these randomized
trials have reported a small but significantly greater CVD
risk reduction in the intervention groups [6].
No randomized trials were found specifically assessing
the tangible health benefits associated with the use of
the non-laboratory based risk assessment algorithms.
However the beneficial trend observed with the labora-
tory based risk assessment algorithms can reasonably be
expected to occur with the implementation of the non-
laboratory based risk assessment algorithms. This may
be especially true in low resource countries where the
use of these tools could have an important role in direct-
ing preventive and treatment efforts toward those in
greatest need.
Limitations
It is possible that our search strategy using the four data-
bases may not have included studies published elsewhere.
However, the selected databases are widely used, and are
well known for their comprehensive repository of high
quality peer reviewed medical articles. Another potential
limitation is that this systematic review may have been
constrained by reliance on the published results of the
reviewed algorithms. The authors of the algorithms might
have carried out additional analyses relative to Cooney’s
criteria, but the information was not publically available to
include in this systematic review.
Summary
The Gaziano and Framingham non-laboratory based algo-
rithms met the majority of the specified criteria for appro-
priateness of statistical methods used to derive the
algorithms and endpoints. Both were derived from ad-
equately powered samples using valid statistical methods.
In addition, their derivation samples were inclusive of
men and women of all adult age groups, and had clearly
defined endpoints. Whereas the Swedish Consultation
based method and the UK General Practice model were
also derived using valid statistical methods, their deriv-
ation samples were small which may have denied them ad-
equate statistical power. In addition, the samples were not
inclusive as evidenced by the UK General Practice model’s
failure to include men, and younger and middle aged
women; and the Swedish Consultation based method’s
failure to include younger and older adult populations.
Only the Gaziano non-laboratory based algorithm was de-
rived from a racially and ethnically diverse sample. This
may not be a major shortcoming for other algorithms be-
cause convincing evidence has been presented showing
that CV risk prediction algorithms can be applicable to
populations with different racial and ethnic profiles. No
data were available to evaluate the WHO-non-laboratory
based algorithms on this criterion.
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ation datasets was measured based on the recommended C
statistic of 0.75, the Swedish Consultation based method,
Framingham and Gaziano non-laboratory based algorithm
demonstrated good discrimination, but the UK General
Practice model had poor discrimination. The Framingham
non-laboratory based algorithm demonstrated superior sen-
sitivity and specificity compared to the other algorithms.
The performance and applicability of most of the algo-
rithms in different populations could not be ascertained
because only the Gaziano non-laboratory based algo-
rithm was externally validated, where it demonstrated
good discrimination and calibration. No data were avail-
able to evaluate the WHO-non-laboratory based algo-
rithms on this criterion.
The criterion for usability of algorithms was ad-
equately met by the Gaziano and WHO non-laboratory
based algorithms. Both had chart formats which are
considered simple and user friendly for clinical applica-
tion. The Framingham non-laboratory based algorithm is
only available in spreadsheet and interactive online calcu-
lator format, thus limiting its use in low technology set-
tings. The Swedish Consultation model and UK General
Practice model had no published charts or calculators
which could enable their use in clinical settings.
The ability of additional CVD risk factors to improve
discrimination was assessed for all algorithms except for
the WHO non-laboratory based algorithms. Overall,
only a slight non-cost-effective improvement of the C-
statistic was observed. This indicates that the inclusion
of appropriate risk factors criterion was met by all the
algorithms except the WHO non-laboratory based algo-
rithm which incorporated similar risk factors with the
Gaziano non-laboratory based algorithm, but dropped
cholesterol instead of substituting it with BMI or other
equivalent measure.
No data were found assessing tangible health benefits
associated with the use of any of the non-laboratory based
risk assessment algorithms in clinical settings. However,
tangible benefits can be anticipated in resource con-
strained primary care settings where the algorithms have
an important role in directing preventive and treatment
efforts toward those in greatest need.
Conclusion
Both the Gaziano and Framingham non-laboratory based
algorithms met most of the benchmarks outlined by
Cooney and colleagues as hallmarks of a clinically ro-
bust risk assessment algorithm. Although the WHO/
ISH non-laboratory based algorithms were designed for
use in resource constrained settings, very little informa-
tion has been availed to assess their performance even
in their derivation dataset. The Swedish Consultation
based method and the UK General Practice model arealso limited by lack of charts or calculators which can be
used in clinical settings to assess absolute CVD risk. Exter-
nal validation of the non-laboratory based risk assessment
algorithms in diverse populations will be an important step
in ascertaining their performance and applicability to differ-
ent populations, and to enhance clinicians’ confidence in
using them to guide screening and management of CVD in
resource constrained settings.
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